Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

IMWG consensus on maintenance therapy in multiple myeloma

Open access
Ludwig, Heinz, Durie, Brian G. M., McCarthy, Philip, Palumbo, Antonio, San Miguel, Jésus, Barlogie, Bart, Morgan, Gareth, Sonneveld, Pieter, Spencer, Andrew, Andersen, Kenneth C., Facon, Thierry, Stewart, Keith A., Einsele, Hermann, Mateos, Maria-Victoria, Wijermans, Pierre, Waage, Anders, Beksac, Meral, Richardson, Paul G., Hulin, Cyrille, Niesvizky, Ruben, Lokhorst, Henk, Landgren, Ola, Bergsagel, P. Leif, Orlowski, Robert, Hinke, Axel, Cavo, Michele, Attal, Michel · 2012 · Blood

Abstract

Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review the relevant data. Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival (PFS) significantly in all 6 studies and overall survival (OS) in 3 of them. In elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. A meta-analysis revealed a significant risk reduction for PFS/event-free survival and death. The role of thalidomide maintenance after melphalan, prednisone, and thalidomide is not well established. Two trials with lenalidomide maintenance treatment after autologous stem cell transplantation and one study after conventional melphalan, prednisone, and lenalidomide induction therapy showed a significant risk reduction for PFS and an increase in OS in one of the transplant trials. Maintenance therapy with single-agent bortezomib or in combination with thalidomide or prednisone has been studied. One trial revealed a significantly increased OS with a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction and thalidomide maintenance treatment. Maintenance treatment can be associated with significant side effects, and none of the drugs evaluated is approved for maintenance therapy. Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-11-374249

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 193

Metadata

Authors
Ludwig, H., Durie, B. G. M., McCarthy, P., Palumbo, A., San Miguel, J., Barlogie, B., Morgan, G., Sonneveld, P., Spencer, A., Andersen, K. C., Facon, T., Stewart, K. A., Einsele, H., Mateos, M.-V., Wijermans, P., Waage, A., Beksac, M., Richardson, P. G., Hulin, C., Niesvizky, R., Lokhorst, H., Landgren, O., Bergsagel, P. L., Orlowski, R., Hinke, A., Cavo, M., & Attal, M.
Venue
Blood
Published
2012-03-29
Volume
119
Issue
13
Pages
3003-3015
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2018729528
Cited by
193
References
4
FWCI
19.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IMWG consensus on maintenance therapy in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2011-11-374249
The paper
Ludwig, H., Durie, B. G. M., McCarthy, P., Palumbo, A., San Miguel, J., Barlogie, B., Morgan, G., Sonneveld, P., Spencer, A., Andersen, K. C., Facon, T., Stewart, K. A., Einsele, H., Mateos, M.-V., Wijermans, P., Waage, A., Beksac, M., Richardson, P. G., Hulin, C., . . . Attal, M. (2012). IMWG consensus on maintenance therapy in multiple myeloma. Blood. https://doi.org/10.1182/blood-2011-11-374249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.